• Product name
    Anti-RUNX1 / AML1 (phospho S303) antibody
    See all RUNX1 / AML1 primary antibodies
  • Description
    Rabbit polyclonal to RUNX1 / AML1 (phospho S303)
  • Specificity
    ab55308 detects endogenous levels of AML1 only when phosphorylated at serine 303.
  • Tested applications
    Suitable for: IHC-P, ELISA, WBmore details
  • Species reactivity
    Reacts with: Mouse, Human
  • Immunogen

    Synthetic phosphopeptide derived from human RUNX1/ AML1 around the phosphorylation site of serine 303 (P-I-SP-P-G).

  • Positive control
    • extracts from Jurkat cells.



Our Abpromise guarantee covers the use of ab55308 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P Use a concentration of 4 µg/ml. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
ELISA 1/5000.
WB 1/500 - 1/1000. Detects a band of approximately 60 kDa (predicted molecular weight: 49 kDa).


  • Function
    CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter. Inhibits MYST4-dependent transcriptional activation.
  • Tissue specificity
    Expressed in all tissues examined except brain and heart. Highest levels in thymus, bone marrow and peripheral blood.
  • Involvement in disease
    Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.
    Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.
    Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.
    Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.
    Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.
    Defects in RUNX1 are the cause of familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]. FPDMM is an autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia.
    Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.
    Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.
  • Sequence similarities
    Contains 1 Runt domain.
  • Domain
    A proline/serine/threonine rich region at the C-terminus is necessary for transcriptional activation of target genes.
  • Post-translational
    Phosphorylated in its C-terminus upon IL-6 treatment. Phosphorylation enhances interaction with MYST3.
  • Cellular localization
  • Information by UniProt
  • Database links
  • Alternative names
    • Acute myeloid leukemia 1 antibody
    • Acute myeloid leukemia 1 protein antibody
    • alpha subunit core binding factor antibody
    • AML 1 antibody
    • AML1 antibody
    • AML1 EVI 1 antibody
    • AML1 EVI 1 fusion protein antibody
    • Aml1 oncogene antibody
    • AMLCR 1 antibody
    • AMLCR1 antibody
    • CBF alpha 2 antibody
    • CBF-alpha-2 antibody
    • CBFA 2 antibody
    • CBFA2 antibody
    • Core binding factor alpha 2 subunit antibody
    • Core binding factor runt domain alpha subunit 2 antibody
    • Core-binding factor subunit alpha-2 antibody
    • EVI 1 antibody
    • EVI1 antibody
    • HGNC antibody
    • Oncogene AML 1 antibody
    • Oncogene AML-1 antibody
    • OTTHUMP00000108696 antibody
    • OTTHUMP00000108697 antibody
    • OTTHUMP00000108699 antibody
    • OTTHUMP00000108700 antibody
    • OTTHUMP00000108702 antibody
    • PEA2 alpha B antibody
    • PEA2-alpha B antibody
    • PEBP2 alpha B antibody
    • PEBP2-alpha B antibody
    • PEBP2A2 antibody
    • PEBP2aB antibody
    • Polyomavirus enhancer binding protein 2 alpha B subunit antibody
    • Polyomavirus enhancer-binding protein 2 alpha B subunit antibody
    • Run1 antibody
    • Runt related transcription factor 1 antibody
    • Runt-related transcription factor 1 antibody
    • RUNX 1 antibody
    • Runx1 antibody
    • RUNX1_HUMAN antibody
    • SL3 3 enhancer factor 1 alpha B subunit antibody
    • SL3-3 enhancer factor 1 alpha B subunit antibody
    • SL3/AKV core binding factor alpha B subunit antibody
    • SL3/AKV core-binding factor alpha B subunit antibody
    see all


  • All lanes : Anti-RUNX1 / AML1 (phospho S303) antibody (ab55308) at 1/500 dilution

    Lane 1 : extracts from Jurkat cells.
    Lane 2 : extracts from Jurkat cells, treated with the immunising phosphopeptide.

    Lysates/proteins at 5 µg per lane.

    Goat Anti-Rabbit IgG (H+L)

    Predicted band size : 49 kDa
    Observed band size : 60 kDa (why is the actual band size different from the predicted?)
  • Ab55308 staining human colon. Staining is localized to the nucleus.
    Left panel: with primary antibody at 4 ug/ml. Right panel: isotype control.
    Sections were stained using an automated system (Dako PT Link), at room temperature. Sections were rehydrated and antigen retrieved with the Dako 3-in-1 antigen retrieval buffer, EDTA pH 9.0. Slides were peroxidase blocked in 3% H2O2 in methanol for 10 minutes. They were then blocked with Dako Protein block for 10 minutes (containing casein 0.25% in PBS) then incubated with primary antibody for 20 minutes and detected with Dako Envision Flex amplification kit for 30 minutes. Colorimetric detection was completed with diaminobenzidine for 5 minutes. Slides were counterstained with Haematoxylin and coverslipped under DePeX. Please note that for manual staining we recommend to optimize the primary antibody concentration and incubation time (overnight incubation), and amplification may be required.


This product has been referenced in:
  • Kamikubo Y  et al. Accelerated leukemogenesis by truncated CBF beta-SMMHC defective in high-affinity binding with RUNX1. Cancer Cell 17:455-68 (2010). WB ; Human . Read more (PubMed: 20478528) »

See 1 Publication for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab55308.
Please use the links above to contact us or submit feedback about this product.


Sign up